

Delta-Tocotrienol: Radiation Protection and Effects on Signal Transduction Pathways

Venkataraman Srinivasan, PhD

Mang Xiao, MD

**Principal Investigators
AFRRI, Bethesda, Maryland**

Srinivasan (part 1)

Prophylactic and mitigatory studies in CD2F1 mice


Xiao (part 2)

***In vivo* and *in vitro* hematopoiesis and effects of DT3 on
Erk/mTOR signaling pathway regulation**

**Radiation Countermeasures Symposium
An AFRRI 50th Anniversary Event
June 15, 2011**


Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE 15 JUN 2011		2. REPORT TYPE		3. DATES COVERED 00-00-2011 to 00-00-2011	
4. TITLE AND SUBTITLE Delta-Tocotrienol: Radiation Protection And Effects On Signal Transduction Pathways				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Armed Forces Radiobiology Research Institute ,Bethesda,MD,20814				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES Presented during the Radiation Countermeasures Symposium, June 15, 2011 Armed Forces Radiobiology Research Institute at the Uniformed Services University in Bethesda, Maryland					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Same as Report (SAR)	18. NUMBER OF PAGES 24	19a. NAME OF RESPONSIBLE PERSON
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			

Experimental Design (Radiation survival studies)




1. Positive control=5-AED and vehicle PEG-400; 24 h pre-TBI
2. 12-14 week old
3. Cobalt 60 gamma radiation

Time Optimization with DT3




Satyamitra et al 2011 *Rad Res* 175, 736

DRF for DT3 (-24 h, sc)





DRF DT3 (2 h postirradiation sc)





Hematology

DT3- 300 mg/kg, -24 h, sc , 7 Gy @ 0.6 Gy/min



Hematology (Ctd)

DT3- 300 mg/kg, -24 h, sc , 7 Gy @ 0.6 Gy/min



Preliminary studies

Oral formulations

Pharmacokinetics (SC and Oral)

**Survival studies
with oral formulations**

Oral formulations of DT3

(in collaboration with Yasoo health)


Emulsions

1. **DT3 in Emulsifier 1** (JH-V-107)
2. **DT3 in Emulsifier 2** (JH-V-101.3)




Tween 80, Brij combinations

Prodrugs

1. **DT3 Glycinate** (JH-V-91.2)
2. **DT3 Succinate** (JH-V-103.2)
3. **DT3 Glucoside** (JH-V-119)




HPLC analysis and Pharmacokinetics (Sc and oral) of DT3



Survival: Oral formulations (% 30 day)

Design: Pre- 4 daily gavage (last dose -24 h)

Post- 4 daily gavage (first dose 1 h postirradiation)



	DT3 dose (mg/kg)	Vehicle	<u>DT3 in emulsifiers (EM)</u>	
			Pre	Post
<u>EM1</u>	75	25	25	56
<u>EM2</u>	100	25	25	25
			<u>DT3 as Prodrugs</u>	
<u>Glycinate</u>	225	6	6	19
<u>Succinate</u>	240	19	13	38
<u>Glucoside</u>	225	37*	38	44 (75)
* contains 10% ethanol				

Introduction

(part 2- Xiao)

Promising candidates identified in a rodent system require further extensive mechanistic studies for FDA approval under the Animal Efficacy Rule.


In the present study, we investigated the radioprotective mechanisms of DT3 on γ -irradiated CD2F1 mouse bone marrow and human hematopoietic progenitor CD34+ cells.

Mouse bone marrow (sternum) pathological changes





Control, 0 Gy



Vehicle, 8.75 Gy





DT3, 8.75 Gy





8 days post-irradiation

Effects of DT3 on recovery of mouse bone marrow myeloid cells from radiation damage (*in vivo*)



DT3 300mg/kg, SC. N = 6

DT3 protected human hematopoietic progenitor CD34+ cells (*in vitro*) from radiation damage




DT3 2 μ M/mL, 24 h before radiation



Survival of γ -irradiated mouse bone marrow and primary human hematopoietic CD34+ cells was significantly enhanced by Delta-tocotrienol (DT3).

Mechanisms?

Radiation-induced activation of intracellular signal pathways






DT3 induced Erk1/2 phosphorylation in CD34+ cells



Normal human hematopoietic CD34+ cells have little or no Erk phosphorylation [Ricciardi et al. *Leukemia*. 2005;19:1543-1549], and the phosphorylated Erk expression was very low or undetectable after γ -irradiation in CD34+ cells.

DT3 reversed the radiation-inhibited mTOR and S6 protein activation and induced 4EBP-1 phosphorylation in CD34+ cells





mTOR: Mammalian target of rapamycin

4EBP-1: Eukaryotic translation initiation factor 4E-binding protein 1


S6: Ribosomal protein

mTOR is a member of the phosphoinositid 3-OH kinase (PI3K)-related kinase family factors which involved in cell proliferation, cell cycle progression, DNA damage checkpoints and cell survival and growth.


DT3 induced Erk phosphorylation in mouse bone marrow cells after irradiation (*in Vivo*)




Erk gene knockdown suppressed m-TOR phosphorylation and clonogenicity in DT3-treated CD34+ cells after IR



C Clonogenicity of DT3-treated CD34+ cells



DT3 induced Erk phosphorylation in γ -irradiated CD34+ cells and protected cells from irradiation-induced DNA-damage



Immunofluorescence staining using anti- γ -H2AX-Rhodamine (red) and anti-phospho-Erk-FITC (green) antibodies. DAPI (blue) defined the cell nucleus.

Summary and Conclusions

- Survival of γ -irradiated mouse bone marrow and primary human hematopoietic CD34+ cells was significantly enhanced by Delta-tocotrienol (DT3).
- DT3 dramatically induced Erk phosphorylation and decreased the DNA-damage marker γ -H2AX foci formation.
- DT3 reversed the radiation-inhibited mTOR and S6 protein activation, and induced 4EBP-1 phosphorylation.
- Knockdown of *Erk* gene expression by siRNA abrogated DT3-induced mTOR phosphorylation, induced γ -H2AX foci formation, and inhibited clonogenicity in CD34+ cells.

In conclusion, our data suggest DT3 effectively protects mouse bone marrow and human CD34+ cells from radiation damage through the Erk/mTOR survival pathway (Hematological 2010; 95(12) 1996-2004).

Acknowledgments



AFRRI

Radiation Countermeasures Program

Mang Xiao, MD. (Group)*

Xiang Hong Li

CPT. Nabil Latif

Dadin Fu, PhD.

Cam T. Ha, PhD.

Venkataraman Srinivasan , PhD. (Group)**

Conor Mullaney

Patrick Ney

Merriline Satyamitra, PhD.

Donald Condliffe

Mark H. Whitnall, PhD. (Advisor, Countermeasure program)

Veterinary Sciences Department Staff

MAJ. Steven R. Mog

MAJ. Eric D. Lombardini

MAJ. Krinon Moccia

Cobalt Facility Staff

Vitaly Nagy, PhD.

William A. Melendez-cruz,

Scientific Directorate and Research Support Group

Christopher R. Lissner, PhD.

Terry C. Pellmar, PhD.

CDR. John R. Gilstad

Lt Col Michael P. Dempsey

Fred Hutchinson Cancer Research Center

NIH Hematopoietic Cell Processing Core (Human CD34+ cells): Shelly Heimfeld, PhD.

*Xiao- Funding: AFRRI Intramural, Congressional project (2009-2012)

**Srinivasan: NIAID-AFRRI-IAA (2006-current), DTRA (2006-2010), AFRRI Intramural